Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 1999

View Archived Issues

Piracetam approved in Japan for cortical myoclonus Rx

Isis presents clinical data at AACR-NCI-EORTC meeting; Novartis withdraws from collaboration

British Biotech makes tangible progress during past six months

MonteGen offers potent antithrombotic agent for licensing

Biomatrix regains exclusive marketing rights to Synvisc in Canada

Cel-Sci begins cancer collaboration in Germany

Dynavax and Stallergenes to develop seasonal allergy therapy

Biomira enters collaborative agreement, licenses two patents for cancer vaccine

GlycoDesign and Seikagaku collaborate on antiinflammatory drugs

Enrollment completed in Inflammatics' phase I/II trial of LeukoVAX in RA

Schering AG will handle marketing and sales of Levulan for Dusa; U.S. launch in sight

Tularik reviews T-138067 clinical data and presents new related compound

Water-soluble paclitaxel derivatives developed at Canadian university

Vertex continues to search for new IMP dehydrogenase inhibitors

Bacterial enzyme inhibitors described by SB

Pfizer discloses modulators of cholinergic function for smoking cessation, etc.

Orally bioavailable sPLA2 inhibitor designed at Lilly

Novel fibrinolytics recently patented by ADIR

L-158809-loaded microspheres assessed in rat model for ability to inhibit restenosis

D-0870-loaded nanospheres highly effective in mouse model of Chagas' disease

Lack of PK interaction between Ziracin and gentamicin demonstrated in humans

Topical formulations of ABT-281 in development according to 1999 AAPS presentations

Animal pharmacokinetics and metabolism of OSU-6162 characterized

Lundbeck presents enhanced R&D pipeline; company will not market Parkinsan outside Germany

Coadministration of betamipron may reduce risk of nephrotoxicity with tenofovir DF

Clinical trials with IDEC-114 begin following favorable safety and pharmacokinetic results in chimps

Ortho-McNeil to acquire Cygnus drug delivery assets

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...